EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current perspectives of cardio‐oncology: Epidemiology, adverse effects, pre‐treatment screening and prevention strategies

Jakub Bychowski iD, Wojciech Sobiczewski iD

Cancer Medicine · 2023-07 · 12 (13) · 14545-14555

DOI: 10.1002/cam4.5980 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 27.04.2023. Verfasst von Jakub Bychowski und 1 weiteren Autor:innen. Beteiligte Einrichtung: 1st Department of Cardiology, Medical University of Gdansk, Gdansk, Poland. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Heart Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer and cardiac diseases are the most prevalent causes of death in most developed countries. Due to the earlier detection and higher effectiveness of treatment, more patients survive the disease and have a long life expectancy. As the post‐cancer population is growing, an increasing number of patients will be diagnosed with sequelae of those therapies, most often affecting the cardiovascular system. Although the risk of cancer recurrence decreases within years, the risk of cardiac complications—for example left ventricle (LV) systolic and diastolic dysfunction, arterial hypertension, arrhythmias, pericardial effusion and premature coronary artery disease remains elevated for decades after the completion of the therapy. The most common anticancer therapies that can cause adverse cardiovascular effects include chemotherapy—in particular anthracyclines, human epidermal growth receptor 2 targeted drugs and radiation therapy. A new field of research, cardio‐oncology, addresses this increasing risk, screening, diagnosis and prevention. This review aims to present the most relevant reports regarding the adverse cardiac effects of oncological therapy, including the most prevalent types of cardiotoxicity, methods of pre‐treatment screening and indications for prevention therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsHeart DiseasesHumansHeartMedical OncologyCardiotoxicity

Stichwörter der Autor:innen

cancer treatmentcardio-oncologycardiotoxicitycardiovascular disease

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • 1st Department of Cardiology, Medical University of Gdansk, Gdansk, Poland.

ORCID-Profile: Jakub Bychowski, Wojciech Sobiczewski

Zitieren

APA

Bychowski, J., & Sobiczewski, W. (2023). Current perspectives of cardio‐oncology: Epidemiology, adverse effects, pre‐treatment screening and prevention strategies. Cancer Medicine, 12(13), 14545-14555. https://doi.org/10.1002/cam4.5980

Vancouver

Bychowski J, Sobiczewski W. Current perspectives of cardio‐oncology: Epidemiology, adverse effects, pre‐treatment screening and prevention strategies. Cancer Medicine. 2023;12(13):14545-14555. doi:10.1002/cam4.5980

BibTeX
@article{Bychowski2023,
  author = {Bychowski, Jakub and Sobiczewski, Wojciech},
  title = {Current perspectives of cardio‐oncology: Epidemiology, adverse effects, pre‐treatment screening and prevention strategies},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {13},
  pages = {14545--14555},
  doi = {10.1002/cam4.5980}
}
Kostenlos starten →